Core Insights - Leslie Storms, President of Johnson & Johnson MedTech's U.S. Orthopedics, announced her departure after an 18-year career, marking a significant transition for the company as it undergoes internal restructuring [2][4][7] - The separation of the orthopedic business, DePuy Synthes, into an independent entity is part of Johnson & Johnson's strategy to focus on faster-growing and higher-margin core areas, including minimally invasive surgery and cardiovascular interventions [4][8] - The leadership change is seen as a critical component of the company's new strategic layout, aiming to enhance operational efficiency and market responsiveness [4][8] Company Strategic Background - Johnson & Johnson is accelerating its global business restructuring, with plans announced in October 2025 to spin off its orthopedic segment, DePuy Synthes, into a standalone company [4] - This decision is intended to allow the group to concentrate on high-value areas and improve the strategic autonomy of its business units [4] - The transition signifies a shift from a comprehensive medical technology platform to a more focused innovation group, with DePuy Synthes' independent development path becoming a key indicator of Johnson & Johnson's business transformation [4] Leadership Profile - Leslie Storms has held various senior management roles within Johnson & Johnson, including positions in global sales and marketing, and has been instrumental in driving digital sales transformation in the surgical instruments sector [7] - As President of Johnson & Johnson's U.S. Orthopedics, she led initiatives to optimize the product line and promote clinical adoption of advanced orthopedic solutions [7] - Storms is recognized for her emphasis on team culture and women's leadership, having co-founded the "Women in MedTech" initiative within the company [7] Conclusion - The departure of Leslie Storms signifies a new adjustment phase for Johnson & Johnson's orthopedic business as it moves towards independence [7] - The company's focus is shifting from a broad coverage model to a more efficient and strategic approach, aiming to solidify its competitive advantage in the global medical technology sector [7][8]